Tirofiban (tirofiban): Reviews and patient testimonials

Tirofiban 12.5mg/250ml infusion bags (50 micrograms/ml in 250ml bags)

Tirofiban is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from Tirofiban treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Tirofiban is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI (see sections 4.2 and 5.1).

Tirofiban is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

Tirofiban 50 micrograms/ml Solution for Infusion

Tirofiban is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from Tirofiban treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Tirofiban is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI (see sections 4.2 and 5.1).

Tirofiban is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

Tirofiban 50 micrograms/ml solution for infusion

Tirofiban is indicated for the prevention of early myocardial infarction in adult patients presenting acute coronary syndromes without ST elevation (NSTE-ACS)with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from tirofiban treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI) . Tirofiban is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI (see section 4.2 and 5.1).

Tirofiban is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

Route of administration: Injectable
Molecule: tirofiban